GxP Brain
GxP Brain is recorded as a service provider in 15 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 15 of 15 trials · Latest update first
A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with active mild to moderate ulcerative colitis for the induction of remission.
Sponsor Faes Farma S.A.
- Start (EU)
- Latest update
- Estimated end
An Open Label, Phase 2 Clinical Trial of MEN1703 as Monotherapy and in Combination with Glofitamab in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
Sponsor Ryvu Therapeutics S.A.
- Start (EU)
- Latest update
- Estimated end
Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia (“PRO-SID” study).
Sponsor Octapharma Pharmazeutika Produktionsgesellschaft mbH
- Start (EU)
- Latest update
- Estimated end
Operational learnings available6 trial-level findings · Read insights
- Of 336 screened patients, 102 initially failed screening; 15 were rescreened and 13 subsequently became eligible.
- Protocol Version 5.0 excluded confirmed COVID-19 from the major-infection definition for the primary endpoint and clarified the effect of altered COVID-19 hospital-admission criteria on major-infection reporting.
- Protocol Version 6.0 permitted repeat IgG testing during screening and rescreening for any patient who failed screening.
- Protocol Version 6.0 removed the scheduled additional safety-panel laboratory visit 7–10 days after the first investigational-product infusion.
- Protocol Version 7.0 added sites in Türkiye, Greece, Spain, and the Czech Republic, removed Israel, and increased the planned site count from approximately 50 to 70.
- No global trial interruptions or restarts were reported.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 2a, Multi-Center, Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of PRA023 in Subjects with Moderately to Severely Active Crohn’s Disease
Sponsor Prometheus Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
Phase 3, double-blind, placebo-controlled, multicentre study on the efficacy and safety of human plasma derived antithrombin (Atenativ) in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass
Sponsor Octapharma AG
- Start (EU)
- Latest update
- Estimated end
An Interventional Study to Evaluate Treating to a Target of Transmural Healing in Patients with Moderately to Severely Active Crohn’s Disease (VECTORS)
Sponsor Alimentiv Inc.
- Start (EU)
- Latest update
- Estimated end
Efficacy of Vitex agnus-castus BNO 1095 (20 mg) in women with primary dysmenorrhea
Sponsor Bionorica SE
- Start (EU)
- Latest update
- Estimated end
- Not reported
Prospective, multicenter, randomized, double-blind, parallel group, placebo-controlled, efficacy and safety phase 3 study of an intravenous human plasma-derived C1 esterase inhibitor (C1-INH) concentrate in participants with congenital C1-INH deficiency for the treatment and pre-procedure prevention of acute hereditary angioedema attacks
Sponsor Octapharma Pharmazeutika Produktionsgesellschaft mbH
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Panzyga for Prevention of Major Infections in Patients with Hypogammaglobulinemia and Autoimmune or Rheumatic Conditions Receiving Treatment with B-cell Depletion Therapy ("PROTECT")
Sponsor Octapharma Pharmazeutika Produktionsgesellschaft mbH
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Induction Therapy with PRA023 in Subjects with Moderately to Severely Active Ulcerative Colitis
Sponsor Prometheus Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
VERDICT: In actiVE ulcerative colitis, a RanDomIzed Controlled Trial for determination of the optimal treatment target
Sponsor Alimentiv Inc.
- Start (EU)
- Latest update
- Estimated end
Study of four-factor prothrombin complex concentrate, OCTAPLEX, in patients with acute major bleeding on direct oral anticoagulant (DOAC) therapy with factor Xa inhibitor.
Sponsor Octapharma AG
- Start (EU)
- Latest update
- Estimated end
A multicentre, single arm trial on contraceptive efficacy, safety and tolerability of LVDS (Levonorgestrel Vaginal Delivery System) during 13 cycles.
Sponsor Chemo Research S.L.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A pivotal, multicentre, randomised, open-label, parallel-group trial on contraceptive efficacy, safety and tolerability of LVDS (Levonorgestrel Vaginal Delivery System) during 9 cycles in comparison with Desogestrel tablets 0.075 mg.
Sponsor Chemo Research S.L.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A superiority phase III study to compare the effect of Panzyga versus placebo in patients with pediatric acute-onset neuropsychiatric syndrome
Sponsor Octapharma Pharmazeutika Produktionsgesellschaft mbH
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for GxP Brain?
The 2026-10-09 snapshot links GxP Brain to 15 distinct CTIS trials. Recorded services include Interactive response technology (IRT), Randomization, Electronic data capture. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for GxP Brain?
The most frequently recorded therapeutic areas are Haematological Malignancies, Immunology, Gastroenterology. Recorded phases include Phase 3, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to GxP Brain conducted?
The linked trials record locations in 21 countries, including Poland, Czechia, Germany, Spain, France. These are trial locations, not confirmed office locations or countries where GxP Brain delivered services.
What can this page tell me about GxP Brain's trial experience?
Browse 15 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under GxP Brain. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- GxP Brain GmbH